Data from: Unlocking the therapeutic potential of T-DXd (Enhertu): Insights into mechanisms of action in HER2-low cancers and immunomodulatory effects
Publication
, Dataset
Spasojevic, I; Fan, P
August 7, 2024
These data are produced by LC/MS/MS analysis of plasma and tumor samples collected in mouse tumor treatment studies, utilizing T-Dxd (Enhertu) is a novel antibody-drug-conjugate (ADC) targeting HER2. After development of fit-for-purpose assays on Shimadzu 20A series/Applied Biosystems-SCIEX LC/MS/MS, study samples were assayed against calibration standard samples and peak area integration and quantification was performed by Analyst 1.6.2.
Duke Scholars
Citation
APA
Chicago
ICMJE
MLA
NLM
Spasojevic, I., & Fan, P. (2024). Data from: Unlocking the therapeutic potential of T-DXd (Enhertu): Insights into mechanisms of action in HER2-low cancers and immunomodulatory effects. https://doi.org/10.7924/r4862qh18
Spasojevic, Ivan, and Ping Fan. “Data from: Unlocking the therapeutic potential of T-DXd (Enhertu): Insights into mechanisms of action in HER2-low cancers and immunomodulatory effects,” August 7, 2024. https://doi.org/10.7924/r4862qh18.
Spasojevic, Ivan, and Ping Fan. Data from: Unlocking the therapeutic potential of T-DXd (Enhertu): Insights into mechanisms of action in HER2-low cancers and immunomodulatory effects. 7 Aug. 2024. Manual, doi:10.7924/r4862qh18.